Sterilizing activity of spectinamide MBX-4888A when replacing linezolid in the Nix-TB regimen in the relapsing BALB/c mouse model of tuberculosis
Antimicrobial Agents and Chemotherapy · 2025
DOI: 10.1128/aac.01183-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Nathan Peroutka-Bigus und 13 weiteren Autor:innen. Beteiligte Einrichtung: Mycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA. Hauptthemen laut MEDLINE: Linezolid, Antitubercular Agents, Mycobacterium tuberculosis, Spectinomycin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Spectinamides have garnered interest as experimental tuberculosis therapeutics owing to their safety profile and efficacy as partner agents when used in conjunction with established regimens in mice. The Nix-TB regimen of bedaquiline, pretomanid, and linezolid represents a short, effective regimen recommended for treatment of pre-extensively drug-resistant tuberculosis. However, linezolid administration is associated with severe adverse events that limit its use. Here we present preclinical data comparing Nix-TB regimens anchored by either linezolid or spectinamide MBX-4888A.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Mycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.
- Center for Discovery and Innovation, Hackensack Meridian School of Medicine, Nutley, New Jersey, USA.
- Microbiotix, Inc., Worcester, Massachusetts, USA.
- Department of Chemical Biology & Therapeutics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
- Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
ORCID-Profile: Nathan Peroutka-Bigus, Terry Bowlin, Bernd Meibohm, Mercedes Gonzalez-Juarrero, Richard E Lee, Gregory T Robertson
Förderung
- NIAID NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Peroutka-Bigus, N., Scherman, M. S., Kaya, F., Waidyarachchi, S. L., Liu, J., Rushefsky, J. N., Butler, M. M., Bowlin, T., Meibohm, B., Gonzalez-Juarrero, M., Lenaerts, A. J., Zimmerman, M., Lee, R. E., & Robertson, G. T. (2025). Sterilizing activity of spectinamide MBX-4888A when replacing linezolid in the Nix-TB regimen in the relapsing BALB/c mouse model of tuberculosis. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01183-25
Vancouver
Peroutka-Bigus N, Scherman MS, Kaya F, Waidyarachchi SL, Liu J, Rushefsky JN, et al. Sterilizing activity of spectinamide MBX-4888A when replacing linezolid in the Nix-TB regimen in the relapsing BALB/c mouse model of tuberculosis. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.01183-25
BibTeX
@article{PeroutkaBigus2025,
author = {Peroutka-Bigus, Nathan and Scherman, Michael S and Kaya, Firat and Waidyarachchi, Samanthi L and Liu, Jiuyu and Rushefsky, Joel N and Butler, Michelle M and Bowlin, Terry and Meibohm, Bernd and Gonzalez-Juarrero, Mercedes and Lenaerts, Anne J and Zimmerman, Matthew and Lee, Richard E and Robertson, Gregory T},
title = {Sterilizing activity of spectinamide MBX-4888A when replacing linezolid in the Nix-TB regimen in the relapsing BALB/c mouse model of tuberculosis},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
doi = {10.1128/aac.01183-25}
}
EUVIMED